Print Page  Close Window

2019 Press Releases

Keyword Search
 
DateTitle 
03/12/19Neurocrine Biosciences Reports Positive Interim Results from Phase II Study of NBI-74788 in Adults with Classic Congenital Adrenal Hyperplasia
- NBI-74788 Achieved Study Goals and Demonstrated Reductions in Key Disease Biomarkers Exceeding Predetermined Threshold for Proof-of-Concept - Based on Interim Results, Company Plans to Meet with FDA to Discuss the Registration Program in Adult and Pediatric Patients with Congenital Adrenal Hyperplasia SAN DIEGO, March 12, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced positive interim results from a Phase II proof-of-concept study evaluating the safety, ... 
Printer Friendly Version
03/05/19Neurocrine Biosciences to Present at Upcoming Healthcare Conferences
SAN DIEGO, March 5, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that Kevin Gorman, Chief Executive Officer, and Matt Abernethy, Chief Financial Officer, of Neurocrine Biosciences will present at the following investor conferences: Cowen 39th Annual Health Care Conference at 10:00 a.m. ET on Tuesday, March 12, 2019, in Boston. Barclays Global Healthcare Conference at 11:15 a.m. ET on Wednesday, March 13, 2019, in Miami. ... 
Printer Friendly Version
02/05/19Neurocrine Biosciences Reports Fourth Quarter and Year-End 2018 Financial Results
INGREZZA® (valbenazine) Fourth Quarter Net Product Sales of $130.3 Million with Approximately 22,900 TRx INGREZZA® (valbenazine) Full-Year 2018 Net Product Sales of $409.6 Million with Approximately 71,500 TRx Congenital Adrenal Hyperplasia Phase II Study Initial Results Expected in Q1 2019 Neurocrine Biosciences and Voyager Therapeutics Form Strategic Gene Therapy Collaboration for Key Neuroscience Programs SAN DIEGO, Feb. 5, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ... 
Printer Friendly Version
01/29/19Neurocrine Biosciences and Voyager Therapeutics Form Strategic Development and Commercialization Collaboration for Parkinson’s Disease and Friedreich’s Ataxia
Collaboration leverages strengths and efforts of both companies towards developing and commercializing life-changing treatments for severe neurological diseasesNeurocrine Biosciences gains development and commercialization rights to gene therapy programs VY-AADC for Parkinson’s disease, VY-FXN01 for Friedreich’s ataxia and two additional programs to be determinedVoyager receives $165 million upfront, along with funding for ongoing development of each program, and up to $1.7 billion in potential ... 
Printer Friendly Version
01/16/19New INGREZZA® (valbenazine) Analysis Published in the Journal of Affective Disorders Demonstrates Sustained Improvement in Tardive Dyskinesia Symptoms in Patients with Primary Mood Disorders
INGREZZA Significantly Reduced the Symptoms of Involuntary Movements in Patients with Bipolar or Major Depressive Disorder in Post-Hoc Analysis Patients Treated with INGREZZA Able to Remain on Existing Psychiatric Medications SAN DIEGO, Jan. 16, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that a new analysis of INGREZZA® (valbenazine) capsules, published in the Journal of Affective Disorders1, demonstrated sustained improvement in tardive dyskinesia (TD... 
Printer Friendly Version
01/15/19Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2018 Financial Results
Conference Call and Webcast Scheduled for Tuesday, February 5 SAN DIEGO, Jan. 15, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it will report fourth quarter and year-end 2018 financial results after the Nasdaq market closes on Tuesday, Feb. 5, 2019. Neurocrine will then host a conference call and webcast to discuss its financial results and provide a Company update that day at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time). ... 
Printer Friendly Version
01/06/19Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2018 Net Product Sales Results and 2019 Program Milestones
- INGREZZA® (valbenazine) Preliminary Fourth Quarter Net Product Sales of Approximately $130 Million with Approximately 22,900 TRx - INGREZZA® (valbenazine) Preliminary Full-Year 2018 Net Product Sales of Approximately $409 Million with Approximately 71,500 TRx SAN DIEGO, Jan. 6, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today provided an update on its business performance, including preliminary net product sales results for 2018, and key clinical development program... 
Printer Friendly Version
01/02/19Neurocrine Biosciences to Present at the 37th Annual J.P. Morgan Healthcare Conference
Live Audio Webcast will be on January 7, 2019 SAN DIEGO, Jan. 2, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) will present at the 37th Annual J.P. Morgan Healthcare Conference at 2:30 p.m. PT (5:30 p.m. ET) on Monday, Jan. 7, 2019, in San Francisco. Kevin Gorman, Chief Executive Officer, will present at the conference. The live presentation will be webcast and may be accessed on the Company's website under Investors at www.neurocrine.com.... 
Printer Friendly Version